PSTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PSTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Poseida Therapeutics's annualized net income for the quarter that ended in Dec. 2023 was $-101.40 Mil. Poseida Therapeutics's average shareholder tangible equity for the quarter that ended in Dec. 2023 was $108.13 Mil. Therefore, Poseida Therapeutics's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 was -93.77%.
The historical rank and industry rank for Poseida Therapeutics's Return-on-Tangible-Equity or its related term are showing as below:
During the past 7 years, Poseida Therapeutics's highest Return-on-Tangible-Equity was -38.47%. The lowest was -256.06%. And the median was -74.75%.
The historical data trend for Poseida Therapeutics's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Poseida Therapeutics Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Return-on-Tangible-Equity | Get a 7-Day Free Trial | - | -256.06 | -61.40 | -38.47 | -88.10 |
Poseida Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Return-on-Tangible-Equity | Get a 7-Day Free Trial | -67.86 | -93.03 | -77.95 | -102.57 | -93.77 |
For the Biotechnology subindustry, Poseida Therapeutics's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Poseida Therapeutics's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Poseida Therapeutics's Return-on-Tangible-Equity falls into.
Poseida Therapeutics's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as
Return-on-Tangible-Equity | = | Net Income | / | ( (Total Tangible Equity | + | Total Tangible Equity) | / count ) |
(A: Dec. 2023 ) | (A: Dec. 2022 ) | (A: Dec. 2023 ) | |||||
= | Net Income | / | ( (Total Stockholders Equity - Intangible Assets | + | Total Stockholders Equity - Intangible Assets ) | / count ) | |
(A: Dec. 2023 ) | (A: Dec. 2022 ) | (A: Dec. 2023 ) | |||||
= | -123.43 | / | ( (182.047 | + | 98.153 ) | / 2 ) | |
= | -123.43 | / | 140.1 | ||||
= | -88.10 % |
Poseida Therapeutics's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 is calculated as
Return-on-Tangible-Equity | = | Net Income | / | ( (Total Tangible Equity | + | Total Tangible Equity) | / count ) |
(Q: Dec. 2023 ) | (Q: Sep. 2023 ) | (Q: Dec. 2023 ) | |||||
= | Net Income | / | ( (Total Stockholders Equity - Intangible Assets | + | Total Stockholders Equity - Intangible Assets) | / count ) | |
(Q: Dec. 2023 ) | (Q: Sep. 2023 ) | (Q: Dec. 2023 ) | |||||
= | -101.396 | / | ( (118.112 | + | 98.153) | / 2 ) | |
= | -101.396 | / | 108.1325 | ||||
= | -93.77 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.
Poseida Therapeutics (NAS:PSTX) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Thank you for viewing the detailed overview of Poseida Therapeutics's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
John P. Schmid | director | 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121 |
Luke Corning | director | 614 DAVIS STREET, EVANSTON IL 60201 |
Marcea Bland Lloyd | director | 9360 TOWNE CENTRE DRIVE, SUITE 110, SAN DIEGO CA 92121 |
Charles M Baum | director | C/O MIRATI THERAPEUTICS INC., 9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO CA 92121 |
Cynthia Collins | director | 65 WEST WATKINS MILL ROAD, GAITHERSBURG MD 20878 |
Rafael Amado | director | 210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080 |
Kristin Yarema | officer: President, Cell Therapy | C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD., SUITE 900, SOUTH SAN FRANCISCO CA 94080 |
Malin Life Sciences Holdings Ltd | 10 percent owner | 2 HARBOUR SQUARE, CROFTON ROAD, DUN LAOGHAIRE, CO, DUBLIN L2 ---- |
Eric Ostertag | director, 10 percent owner, officer: Chief Executive Officer | C/O POSEIDA THERAPEUTICS, INC., 4242 CAMPUS POINT COURT, SUITE 700, SAN DIEGO CA 92121 |
Kerry D. Ingalls | officer: Chief Operating Officer | C/O POSEIDA THERAPEUTICS, INC., 9390 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92121 |
Brent Warner | officer: President, Gene Therapy | C/O POSEIDA THERAPEUTICS, INC., 9390 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92121 |
Matthew A. Spear | officer: Chief Medical Officer | C/O POSEIDA THERAPEUTICS, INC., 4242 CAMPUS POINT COURT, SUITE 700, SAN DIEGO CA 92121 |
Harry J Leonhardt | officer: GC & Chief Compliance Officer | C/O HALOZYME THERAPEUTICS, INC., 11388 SORRENTO VALLEY BLVD., SAN DIEGO CA 92121 |
David Hirsch | director | C/O LONGITUDE CAPITAL PARTNERS, LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025 |
Sean Murphy | director, 10 percent owner | C/O NOVAN, INC., 4222 EMPEROR BOULEVAND, SUITE 200, DURHAM NC 27703 |
From GuruFocus
By PRNewswire PRNewswire • 05-09-2023
By PRNewswire PRNewswire • 01-31-2023
By PRNewswire • 07-05-2023
By PRNewswire PRNewswire • 12-11-2022
By PRNewswire • 08-07-2023
By PRNewswire • 08-08-2023
By PRNewswire • 06-26-2023
By PRNewswire PRNewswire • 12-06-2022
By PRNewswire PRNewswire • 04-11-2023
By PRNewswire PRNewswire • 03-01-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.